Company: TLSA
Filing Date: 2025-03-24
Form Type: F-3
Source: 0001013762-25-001691
Chunk: 55

Company: Tiziana Life Sciences Ltd
Filing Date: 2025-03-24
Form: F-3
Chunk 55
---
 of our common shares and materially adversely affect our ability to raise capital on terms acceptable to us, or at all. Finally, delisting of our common shares could result in our common shares becoming a “penny stock” under the Exchange Act.

<div align='center'>S-8</div>

The prices of the common shares may be volatile and fluctuate substantially, which could result in substantial losses for holders of the common shares.

The market prices of the common shares on The Nasdaq Capital Market may be volatile and fluctuate substantially. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, holders of the common shares may not be able to sell their common shares at or above the price at which they were purchased. The market price for the common shares may be influenced by many factors, including:

| ● | the success of competitive 
 products or technologies;  |

| ● | results of clinical trials                                                                                
 of foralumab, anti-IL6R mAb (TZLS-501), Milciclib and any other future product candidate that we develop; |

| ● | results of clinical trials                
 of product candidates of our competitors; |

| ● | changes or developments                                                                                                          
 in laws or regulations applicable to foralumab, anti-IL6R mAb (TZLS-501), Milciclib and any other future product candidates that 
 we develop;                                                                                                                      |

| ● | our entry into, and the                                      
 success of, any collaboration agreements with third parties; |

| ● | developments or disputes                                                    
 concerning patent applications, issued patents or other proprietary rights; |

| ● | the recruitment or departure 
 of key personnel;            |

| ● | the level of expenses related                                      
 to any of our product candidates or clinical development programs; |

| ● | the results of our efforts                                                                           
 to discover, develop, acquire or in-license additional product candidates, products or technologies; |

| ● | actual or anticipated changes                                                                          
 in estimates as to financial results, development timelines or recommendations by securities analysts; |

| ● | variations in our financial                                           
 results or those of companies that are perceived to be similar to us; |

| ● | market conditions in the                  
 biotechnology and pharmaceutical sectors; |

| ● | general economic, industry 
 and market conditions;     |

| ● | the trading volume of common                                                                         
 shares on The Nas